Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Motesanib

Generic Name: Motesanib

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₃N_₅O

CAS Number: 453562-69-1

Unique Ingredient Identifier: U1JK633AYI

Overview

No overview information available.

Background

No background information available.

Indication

Investigated for use/treatment in solid tumors.

Associated Conditions

No associated conditions information available.

Clinical Trials

Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer

Phase 3

Terminated

Posted: 2015/12/14

Sponsor:Takeda

ID:NCT02629848

Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors

Phase 1

Completed

Posted: 2011/07/01

Sponsor:Amgen

ID:NCT01386866

Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer

Phase 1

Withdrawn

Posted: 2011/05/06

Sponsor:Sidney Kimmel Cancer...

ID:NCT01349088

A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors

Phase 1

Completed

Posted: 2010/11/05

Sponsor:Amgen

ID:NCT01235416

To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.

Phase 1

Completed

Posted: 2009/03/13

Sponsor:Amgen

ID:NCT00861419

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy